A Phase 1 Adaptive Dose-escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)

Trial Profile

A Phase 1 Adaptive Dose-escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Aug 2017

At a glance

  • Drugs ADCT 402 (Primary)
  • Indications Burkitt's lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; MALT lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions
  • Sponsors ADC Therapeutics
  • Most Recent Events

    • 18 Aug 2017 Planned number of patients changed from 135 to 175.
    • 28 Jun 2017 Planned number of patients changed from 60 to 135.
    • 16 Jun 2017 According to an ADC Therapeutics media release, further results are expected later this year.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top